10-K: Vaxcyte Announces Positive Phase 1/2 Data for VAX-31 and Advances Pipeline

Vaxcyte reports positive clinical trial results and progresses its vaccine pipeline, including a breakthrough therapy designation for VAX-31.

Summary

• Vaxcyte, Inc., a clinical-stage vaccine company, has filed its annual report on Form 10-K for the fiscal year ended December 31, 2024.
• The company is focused on developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.
• A key highlight is the positive topline results from a Phase 1/2 study of VAX-31 in adults, showing it was well-tolerated and demonstrated robust immune responses.
• VAX-31 is a 31-valent pneumococcal conjugate vaccine (PCV) candidate designed to cover a broad range of pneumococcal disease serotypes.
• The FDA granted Breakthrough Therapy Designation for VAX-31 in adults.
• The company is also advancing VAX-24, a 24-valent PCV candidate, with topline data from the Phase 2 primary three-dose immunization series expected by the end of the first quarter 2025.
• Vaxcyte initiated a Phase 2 study of VAX-31 in infants in December 2024, with topline data from the primary three-dose immunization series expected in mid-2026.
• The company is also progressing its novel vaccine candidates, including VAX-A1 for Group A Strep, VAX-PG for periodontitis, and VAX-GI for dysentery and shigellosis.
• Vaxcyte has established manufacturing partnerships with Lonza and Sutro Biopharma to support the production of its vaccine candidates.
• The company completed two follow-on financings in 2024, raising $2.4 billion in gross proceeds.
• As of December 31, 2024, Vaxcyte had cash, cash equivalents, and investments of $3.1347 billion.
• The company anticipates that its existing cash, cash equivalents and investments will fund its operating expenses and capital expenditure requirements through at least 12 months from the filing date of the report.

Sentiment

Score: 7

Explanation: The document presents a balanced view with positive clinical trial results and financial stability, but also acknowledges the risks and challenges inherent in vaccine development.

Positives

• Positive clinical data for VAX-31 supports advancement to Phase 3 trials.
• Breakthrough Therapy Designation for VAX-31 could expedite development and review.
• Strong financial position with $3.1347 billion in cash, cash equivalents, and investments.
• Advancement of multiple vaccine candidates in the pipeline, including VAX-24 and VAX-A1.
• Established manufacturing partnerships with Lonza and Sutro Biopharma.

Negatives

• The company has incurred net losses since inception and anticipates continuing to incur substantial net losses for the foreseeable future.
• The company has no products approved for sale and has not generated any revenue from product sales.
• The company is dependent on third-party manufacturers and suppliers, which exposes it to risks related to supply chain disruptions and regulatory compliance.

Risks

• Clinical and preclinical stages of vaccine development are inherently risky and may not lead to successful products.
• Regulatory approval processes are lengthy and time-consuming, and the FDA may disagree with the company's regulatory plan.
• The company faces intense competition from companies with greater resources and experience.
• The company's approach to vaccine development is based on novel technologies that are unproven.
• The company is dependent on the success of its pneumococcal conjugate vaccine candidates, VAX-31 and VAX-24.
• The company may require substantial additional funding to finance its operations, which may not be available on acceptable terms, or at all.

Future Outlook

The company plans to initiate a Phase 3 pivotal, non-inferiority study for VAX-31 by mid-2025 and announce topline safety, tolerability and immunogenicity data in 2026. The company expects to announce topline safety, tolerability and immunogenicity data from the VAX-24 Phase 2 primary three-dose immunization series by the end of the first quarter 2025, followed by topline data from the booster dose by the end of 2025. The company expects to announce topline data from the VAX-31 Phase 2 primary three-dose immunization series in mid-2026, followed by topline data from the booster dose approximately nine months later.

Industry Context

The global vaccine market, excluding COVID-19 vaccines, is projected to reach $80.3 billion by 2029 from $53.0 billion in 2024, a compounded annual growth rate of 8.7%. The company is competing with major players like Pfizer, Merck, and GSK in the pneumococcal vaccine market.

Comparison to Industry Standards

• The Prevnar franchise from Pfizer Inc. (Pfizer) comprised of Prevnar 13 (PCV13) and PCV20, was among the highest selling non-COVID vaccine products in the world in 2024, accounting for approximately 12% of global non-COVID vaccine sales.
• The U.S. adult pneumococcal market generated estimated annual sales of approximately $1 billion to $2 billion in 2024.
• Shingrix, a vaccine for shingles (herpes zoster), debuted with over $1 billion in sales in 2018 and generated over $4.1 billion in global sales in 2024.
• The vaccines to prevent respiratory syncytial virus from Pfizer and GSK that were approved by the FDA in May 2023, and from Moderna that was approved by the FDA in May 2024, have generated nearly $4 billion in global sales as of December 31, 2024.

Stakeholder Impact

• Shareholders: Potential for increased value through successful vaccine development and commercialization.
• Employees: Continued employment and growth opportunities within the company.
• Patients: Access to potentially improved or novel vaccines for bacterial diseases.
• Suppliers: Continued business relationships and potential for increased demand.
• Creditors: Financial stability and ability to meet obligations.

Next Steps

• Initiate a Phase 3 pivotal, non-inferiority study for VAX-31 by mid-2025.
• Announce topline safety, tolerability and immunogenicity data from the VAX-24 Phase 2 primary three-dose immunization series by the end of the first quarter 2025.
• Announce topline data from the VAX-31 Phase 2 primary three-dose immunization series in mid-2026.

Key Dates